Um, and then also, why did you decide to perform this review at this time? What sparked your interest?

Sure.

Yeah.

I mean, I think, you know, first is that the reason really why we're having this conversation, and it kind of g- goes back to a seminal paper back in 2012.

A paper was published in The New England Journal of Medicine.

Um, it was a paper by Nielsen and colleagues out of, uh, Copenhagen.

Uh, they did something that really no one has, uh, done before.

How exactly might a statin prime a tumor to be more vulnerable to these targeted treatments?